Trial Watch - bispecific T cell engagers and higher-order multispecific immunotherapeutics
Over the past decades, cancer immunotherapy has evolved into clinical practice, with bispecific T cell engagers (TCEs) and other higher-order multispecific immunotherapeutics emerging as approaches for precision immune modulation. These engineered antibodies redirect immune effector cells toward tum...
Сохранить в:
| Главные авторы: | , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Taylor & Francis Group
2026-12-01
|
| Серии: | OncoImmunology |
| Предметы: | |
| Online-ссылка: | https://www.tandfonline.com/doi/10.1080/2162402X.2026.2632421 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|